Perspectives on immunotherapy in prostate cancer and solid tumors: Where is the future? Journal Article
| Authors: | Snyder, A.; Tepper, J. E.; Slovin, S. F. |
| Article Title: | Perspectives on immunotherapy in prostate cancer and solid tumors: Where is the future? |
| Abstract: | The goals of any cancer therapy are to improve disease control, palliate pain and improve overall survival. We are fortunate to have in our cancer armamentarium two new immune-directed therapies which not only impact on disease control but also on overall survival. The first, sipuleucel-T, a cellular-based vaccine, was approved for prostate cancer and was shown to be safe with minimal toxicity. The second, ipilimumab, a monoclonal antibody directed to an immunologic checkpoint molecule, showed a survival benefit in patients with advanced melanoma. Benefit appeared to correlate in some cases with the development of autoimmune events, signaling that the immune system is in overdrive against the cancer. Where we are and where we will likely go are the topics to be discussed in this review. © 2013 Elsevier Inc. |
| Keywords: | cancer survival; unclassified drug; overall survival; prednisone; hepatitis; advanced cancer; drug efficacy; nonhuman; solid tumor; bone metastasis; paclitaxel; pancreas cancer; colorectal cancer; carboplatin; cytotoxic t lymphocyte antigen 4 antibody; interleukin 2; ipilimumab; cancer immunotherapy; melanoma; ovary cancer; cell growth; lung non small cell cancer; granulocyte macrophage colony stimulating factor; cancer pain; kidney carcinoma; docetaxel; prostate cancer; prostate specific membrane antigen; immune response; cancer vaccine; colitis; virus load; mucin 1; cancer control; enzyme linked immunospot assay; androgen deprivation therapy; influenza vaccine; influenza; antibody titer; castration resistant prostate cancer; metastatic melanoma; randomized controlled trial (topic); molecularly targeted therapy; phase 2 clinical trial (topic); phase 3 clinical trial (topic); phase 1 clinical trial (topic); hypophysitis; passive immunization; human immunodeficiency virus vaccine; sipuleucel t; belagenpumatucel l; gm2 vaccine; onamelatucel l |
| Journal Title: | Seminars in Oncology |
| Volume: | 40 |
| Issue: | 3 |
| ISSN: | 0093-7754 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2013-06-01 |
| Start Page: | 347 |
| End Page: | 360 |
| Language: | English |
| DOI: | 10.1053/j.seminoncol.2013.04.009 |
| PROVIDER: | scopus |
| PUBMED: | 23806499 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 1 August 2013" - "CODEN: SOLGA" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work